Dr. Roskrow is a haematologist and oncologist trained at the University of London. She has held many high level clinical and research positions, most recently as a leader in translational research at the GSF -National Research Centre for Environment and Health in Munich, Germany. She has extensive experience related to the early and later-stage clinical development of novel anti-cancer compounds and has earned many awards and honours for her work. Complementing her clinical research experience, Dr. Roskrow has worked for several years in healthcare investment banking, most recently at Lazard Ltd. She participated in many public and private biotechnology and pharmaceutical merger and acquisition deals, company financings and product in/out-licensing deals. In addition, Dr Roskrow has an extensive network of relationships with executives and board members of pharmaceutical and biotechnology companies and leading clinical centres.

Mr. McPherson has more than 20 years’ experience in senior finance roles in various industries. His early career included working with a chartered accounting practice and two years with the Australian Taxation Office. Before joining Patrys, Mr. McPherson was Chief Financial Officer and Company Secretary at eChoice Home Loans where he was responsible for financial affairs and corporate administration. Mr. McPherson has over 12 years’ biotechnology and pharmaceutical experience, including four years with Cerylid Biosciences Limited as Chief Financial Officer and Company Secretary, in which capacity he provided strategic direction and information reporting and supported research and development activities. Mr. McPherson spent six years at Amrad Corporation Ltd in various senior finance roles.

Dr. Hensel joined Patrys from OncoMab GmbH, which he co-founded, and held the position of Chief Executive Officer since 2002. Dr. Hensel obtained his PhD from, and later worked in, the laboratory of Dr. Vollmers at the University of Wurzburg. He was closely involved in the discovery and successful development of Patrys’ antibody pipeline and underlying technologies. Dr. Hensel is the Managing Director of wholly owned subsidiary Patrys GmbH, and is responsible for the early stages of development of the Patrys pipeline – target discovery, and antibody production and purification.

Mr. Hedt has over 10 years’ experience in clinical trial management. He was most recently Clinical Study Manager at CSL where he was responsible for managing local and international trials from first-in-human to post-marketing epidemiological studies. He has been involved in trials across a range of indications, including oncology, infectious diseases, and neurology. At Patrys he has responsibility for the local coordination and management of Phase I/II trials for lead products PAT-SM6 and PAT-LM1.

Dr. Greenwood spent the past 10-years in academia conducting immunology research in the areas of vaccine development and autoimmunity, with the last four years at the Centre for Animal Biotechnology, The University of Melbourne. Deanne has managed various research and commercial research projects and collaborations and is responsible for business development, grants, relationship management and Patrys' intellectual property portfolio. Deanne has a PhD degree in Immunology from the Monash University and a Masters of Business Administration (Technology) from La Trobe University.